Alkem Laboratories · NSE: ALKEM · BSE: 539523
Q4 FY20 results · Jan–Mar 2020
Alkem Laboratories reported revenue from operations of ₹2,048.99 crore (up 10.5% from Q4 FY19) and net profit of ₹191.54 crore (up 12.3% from Q4 FY19) for Q4 FY20 (Jan–Mar 2020), on a consolidated basis.
| Item | Q4 FY20 | Q4 FY19 | YoY | Q3 FY20 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 2,048.99 | 1,854.20 | +10.5% | 2,181.84 | −6.1% |
| Other income | 27.47 | 27.66 | −0.7% | 27.86 | −1.4% |
| Total income | 2,076.46 | 1,881.86 | +10.3% | 2,209.70 | −6.0% |
| Profit before tax | 235.30 | 198.81 | +18.4% | 404.61 | −41.8% |
| Net profit for the period | 191.54 | 170.50 | +12.3% | 389.96 | −50.9% |
| Attributable to shareholders of the company | 188.77 | 167.36 | +12.8% | 381.98 | −50.6% |
| EPS, basic (₹) | 15.79 | 14.00 | +12.8% | 31.95 | −50.6% |
| Net margin (%) | 9.3 | 9.2 | 17.9 |
| Item | Q4 FY20 | Q4 FY19 | YoY | Q3 FY20 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 1,687.52 | 1,467.84 | +15.0% | 1,596.40 | +5.7% |
| Other income | 25.92 | 19.07 | +35.9% | 26.75 | −3.1% |
| Total income | 1,713.44 | 1,486.91 | +15.2% | 1,623.15 | +5.6% |
| Profit before tax | 306.43 | 214.65 | +42.8% | 337.80 | −9.3% |
| Net profit for the period | 271.21 | 190.82 | +42.1% | 348.57 | −22.2% |
| EPS, basic (₹) | 22.68 | 15.96 | +42.1% | 29.15 | −22.2% |
| Net margin (%) | 16.1 | 13.0 | 21.8 |
Consolidated
- Filed with BSE
- 05 Jun 2020, 18:44 IST
- Board meeting
- 05 Jun 2020
- Period
- 01 Jan 2020 to 31 Mar 2020
- Review status
- Audited
- Source
- XBRL filing on BSE
Standalone
- Filed with BSE
- 05 Jun 2020, 18:44 IST
- Board meeting
- 05 Jun 2020
- Period
- 01 Jan 2020 to 31 Mar 2020
- Review status
- Audited
- Source
- XBRL filing on BSE